Sirnaomics

Sirnaomics Ltd., a clinical-stage biopharmaceutical company directly under Sirnaomics, Inc., was founded in 2008 by a returned overseas entrepreneurial team led by Dr. YANG LU, a nationally designated expert. The company leverages its extensive knowledge and experience in RNA interference (RNAi) technology to discover and develop drugs targeting diseases with unmet or ineffective clinical treatments, paving the way for high-value new drug creation based on market demands.Since its establishment, the company has focused on constructing a nucleic acid interference drug delivery platform and developing new drug candidates. It is now the only enterprise globally capable of advancing nucleic acid interference drugs into clinical trials simultaneously in both China and the United States, achieving a "zero" breakthrough in China's clinical trials for innovative nucleic acid interference drugs. Sirnaomics Ltd. has completed three rounds of financing and raised $48 million in its Series C round in the first half of 2019.The company focuses on multi-target drug design and, through its proprietary peptide nanoparticle (PNP) core technology, has developed a unique nucleic acid interference drug delivery platform. This improves in vivo drug delivery efficiency, enhances the efficacy of small nucleic acid drugs, addresses clinical treatment needs, and strengthens its market competitiveness.